Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Inozyme gets $67mm via Series A2

Executive Summary

Inozyme Pharma Inc. (developing therapies for rare diseases of calcification) raised $67mm in its Series A2 financing led by Pivotal bioVenture Partners and Sofinnova Investments, which were joined by RA Capital Management, Cowen Healthcare Investments, and Rock Springs Capital, and returning shareholders Longitude Capital, New Enterprise Associates, Novo Holdings, and Sanofi Ventures. Inozyme will use the funds to move its lead enzyme replacement therapy INZ701 into the clinic for severe conditions associated with deficiencies in the enzyme ENPP1, including generalized arterial calcification of infancy and autosomal recessive hypophosphatemic Rickets Type 2. The company is also exploring development of INZ701 for ABCC6 deficiency.

Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies